Terns Pharmaceuticals, Inc.
TERN · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -2.97 | -0.32 | 0.41 | 0.76 |
| FCF Yield | -5.53% | -9.68% | -2.89% | -2.54% |
| EV / EBITDA | -8.22 | -4.18 | -13.42 | -15.37 |
| Quality | ||||
| ROIC | -8.92% | -8.31% | -7.46% | -6.81% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.78 | 1.02 | 0.67 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 22.75% | -67.58% | 11.37% | -1.62% |
| Safety | ||||
| Net Debt / EBITDA | 6.05 | 5.02 | 6.22 | 10.87 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -2,374.17 | 0.00 | 0.00 | 0.00 |